$818M Deal Lowballs Trius On Brink Of Drug Launch, Suit Says

Law360, Wilmington (August 12, 2013, 9:57 PM EDT) -- A Trius Therapeutics Inc. shareholder brought a putative class action Friday aimed at stopping a buyout by Cubist Pharmaceuticals Inc. worth up to $818 million, calling the offer ill-timed and undervalued given the “imminent launch” of the drug developer's first product.

Filed in Delaware Chancery Court, the complaint claims Trius' directors breached their fiduciary duty by approving an offer that would take out shareholders on the cheap just when the company is poised to take off.

The San Diego-based biopharmeceutical company is developing a powerful new...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.